Target: Ly49C.
Clone: 4LO3311.
Specificity: 4LO3311 activity is directed against Ly49C (Killer cell lectin-like receptor 3, KLRA3; NK2.1). 4LO3311 binds an epitope located in a 32-amino acid segment of the stalk region immediately adjacent to the carbohydrate recognition domain.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: Ly49C is expressed on NK, uterine NK, NKT, and CD8+ T cells.
Background: 4LO3311 recognizes an epitope located in a 32-amino acid segment of the stalk region immediately adjacent to the carbohydrate recognition domain. 4LO3311 recognizes Ly-49CBALB but not Ly-49AB6, Ly-49ABALB, BBALB, DB6, EB6, FB6, GB6, GBALB, or H. 4LO3311 plus complement inhibits NK cell and antibody-dependent cellular cytotoxicity (ADCC) activity in C3H spleen cells4. 4LO3311 inhibits C57BL/6 and C3H NK cell activity but has no effect on NZB NK cells.
Immunogen: 4LO3311 was generated by immunizing 129/SvJ mice with C57BL/6 NK-enriched spleen cells.
Concentration: ≥ 2.0 mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.5 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.